Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1. DOI

A.S. Vickram,

Saghya Infant Shofia,

A. Saravanan

и другие.

PubMed, Год журнала: 2024, Номер 23, С. 1303 - 1326

Опубликована: Янв. 1, 2024

The emergence of checkpoint inhibitors targeting the PD-1/PD-L1 axis marks a paradigm shift in cancer therapy, offering novel avenue for enhancing patient outcomes. This review examines structural and functional dynamics PD-1 PD-L1 while exploring clinical implications current monoclonal antibodies. Highlighting recent advancements, this paper delves into promising results from combination therapies that present multifaceted attack on tumor progression. Despite success observed across various types, challenges such as immune resistance remain. Future considerations are discussed with an emphasis need further studies, aiming to refine broaden curative potential oncology. postulates ongoing research innovative approaches could significantly enhance care, making immunotherapy even more central strategy fight against cancer. See also graphical abstract(Fig. 1).

Язык: Английский

Pharmacophore-guided computational modeling of quinolone-ATPase conjugate inhibitors targeting DNA GyrB subunit of Staphylococcus aureus DOI
Md. Al Amin,

Md. Jakir Hossain,

Md. Kawsar Habib

и другие.

Computers in Biology and Medicine, Год журнала: 2025, Номер 186, С. 109727 - 109727

Опубликована: Янв. 25, 2025

Язык: Английский

Процитировано

0
Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implications DOI Creative Commons

Mahalakshmi Devaraji,

Punniyakoti T. Veeraveedu

Cancer Pathogenesis and Therapy, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0
Discovery of Natural MCL1 Inhibitors using Pharmacophore modelling, QSAR, Docking, ADMET, Molecular Dynamics, and DFT Analysis DOI
Uddalak Das,

Tathagata Chanda,

Jitendra Kumar

и другие.

Computational Biology and Chemistry, Год журнала: 2025, Номер 117, С. 108427 - 108427

Опубликована: Март 16, 2025

Язык: Английский

Процитировано

0
Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1. DOI

A.S. Vickram,

Saghya Infant Shofia,

A. Saravanan

и другие.

PubMed, Год журнала: 2024, Номер 23, С. 1303 - 1326

Опубликована: Янв. 1, 2024

The emergence of checkpoint inhibitors targeting the PD-1/PD-L1 axis marks a paradigm shift in cancer therapy, offering novel avenue for enhancing patient outcomes. This review examines structural and functional dynamics PD-1 PD-L1 while exploring clinical implications current monoclonal antibodies. Highlighting recent advancements, this paper delves into promising results from combination therapies that present multifaceted attack on tumor progression. Despite success observed across various types, challenges such as immune resistance remain. Future considerations are discussed with an emphasis need further studies, aiming to refine broaden curative potential oncology. postulates ongoing research innovative approaches could significantly enhance care, making immunotherapy even more central strategy fight against cancer. See also graphical abstract(Fig. 1).

Язык: Английский

Процитировано

0